Hanmi Pharmaceutical's neutropenia drug Rolvedon is cruising in the US market. Rolvedon has surpassed KRW 100 billion in cumulative sales in the US market. Hanmi Pharmaceutical's U.S. partner Assertio plans to further increase the drug’s market share by securing a same-day dosing indication.

According to Assertio on the 18th, Rolvedon generated USD 14.5 million (about KRW 19.7 billion) in sales in Q1 this year, up 31.8% from the USD 11 million it generated in Q4 last year. Since its launch in the US in Q4 2022, Rolvedon has generated USD 80.2  million (KRW 110 billion) in cumulative sales.

Rolvedon (Korean brand name: Rolontis) is a neutropenia treatment developed by Hanmi Pharma